Insulin Medicine Pharma Companies 
Delveinsight
JULY 21, 2021
However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease. It is also known as insulin-dependent diabetes.
World of DTC Marketing
JUNE 16, 2021
KEY POINTS: About three in ten adults report not taking their medicines as prescribed at some point in the past year because of the cost. The public sees profits made by pharmaceutical companies as the largest factor contributing to the price of prescription drugs. Their feeling is that “patients need us more than we need them.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 17, 2023
Specifically, pharma companies are uncertain about when orphan drug exemptions begin, which Jarzyna said could adversely affect innovation. Insulin affordability has continued to prove a hot button topic as major pricing reforms are on the way.
Pharmaceutical Technology
JANUARY 31, 2023
While insulin price caps will begin this year, larger effects will be delayed until 2026 – when the US federal government will be allowed to negotiate Medicare prices and demand rebates from drug companies that price gouge. That leaves three years for pharma companies to prepare. It’s much needed. It’s a hot area.”
XTalks
JANUARY 5, 2024
Eli Lilly launched LillyDirect this week, an online service that provides access to the company’s medicines, including its newly approved weight loss drug Zepbound (tirzepatide). Ricks, Lilly’s chair and CEO, in the company’s announcement. Zepbound was approved by the US Food and Drug Administration (FDA) in November 2023.
pharmaphorum
JULY 13, 2022
And while pharma companies are working hard to find treatments for these diseases, they have a major problem that must be addressed before that work can be done effectively: the lack of objective, quantitative measurement tools for assessing the progression – or even the presence or absence – of these conditions.
XTalks
FEBRUARY 14, 2024
Allocation of Profits, PBMs Under Fire The CEOs defended high prescription drug prices saying that a big chunk of pharma profits go towards funding the research and development of new medicines. Murphy interrogated this claim and specifically questioned the way companies allocate revenue.
Expert insights. Personalized for you.
94 
Let's personalize your content